The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Oct 2014 17:51

RNS Number : 4670T
Advanced Oncotherapy PLC
03 October 2014
 



 

TR-1: Notifications of Major Interests in Shares

 

1: Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Advanced Oncotherapy PLC

 

2: Reason for notification (yes/no)

An acquisition or disposal of voting rights

yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

no

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

no

An event changing the breakdown of voting rights

no

Other (please specify):

 

no

 

3. Full name of person(s) subject to the notification

obligation:

Standard Life Investments (Holdings) Limited (Parent Company) -5.93% comprised of:

Standard Life Investments Limited - 5.93%

Ignis Investment Services Limited -0%

4. Full name of shareholder(s) (if different from 3.):

 Vidacos Nominees\HSBC

5. Date of the transaction (and date on which the threshold

is crossed or reached):

02/10/2014

6. Date on which issuer notified:

03/10/2014

7. Threshold(s) that is/are crossed or reached:

6%

 

8: Notified Details
A: Voting rights attached to shares
Class/type of share If possible use ISIN code
GB00B16JQ761
 
Situation previous to the triggering transaction
Number of shares
Number of voting rights
62,396,477
62,396,477
 
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Percentage ofvoting rights
Direct
Indirect
Direct
Indirect
60,546,477
40,152,498
20,393,979
3.933
1.998
 

 

 

 

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration date
Exercise/ conversion period/date
No. of voting rights that may be acquired(if the instrument exercised/converted)
Percentage of voting rights
 
 
 
 
 
 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

60,546,477

5.931

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

Standard Life Investments (Holdings) Limited (Parent Company) -5.93% comprised of:

Standard Life Investments Limited -5.93%

Ignis Investment Services Limited -0%

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

 

14. Contact name:

 

GIOS@standardlife.comStandard Life Investments Ltd

15. Contact telephone number:

 

(0131) 245 6565

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOSNRSWARRAA
Date   Source Headline
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.